Prosecution Insights
Last updated: November 04, 2026
Application No. 18/852,362

COMPUTER VISION-BASED MONITORING SYSTEM FOR JAUNDICE TREATMENT

Non-Final OA §103
Filed
Sep 27, 2024
Priority
Sep 11, 2023 — PH 12023050495 +1 more
Examiner
HUH, VYNN V
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Ateneo De Manila University
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
1y 3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
182 granted / 294 resolved
-8.1% vs TC avg
Strong +44% interview lift
Without
With
+44.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
32 currently pending
Career history
332
Total Applications
across all art units

Statute-Specific Performance

§101
6.4%
-33.6% vs TC avg
§103
42.1%
+2.1% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
26.2%
-13.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 294 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status: Claims 1-6 are pending. Claim Objections Claim 4 is objected to because of the following informalities: “Wi-Fi” and “Bluetooth technology”. To avoid possibly claiming a trademark, Examiner suggests deleting the limitation “utilizing Wi-Fi or Bluetooth technology”. Appropriate correction is required. Claim 2 is objected to because of the following informalities: there is a grammatical error in “connected the local communication network”. Examiner suggest amending the limitation to “connected to the local communication network”. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-6 are rejected under 35 U.S.C. 103 as being unpatentable over Gobeyn (EP2146635B1) in view of Trau et al. (US 2022/0117525A1) and Butler (US 2004/0008523 A1). Re Claim 1, Gobeyn discloses a computer vision-based jaundice monitoring system, comprising: a. a camera configured to capture an image of a patient (para. [0084], fig. 4, cameras 120 can have an image sensor array 124 (commonly a CCD or CMOS) including sensing pixels overlaid with a patterned color filter array (often RGB)); b. a computing device in communication with the camera, the computing device is programmed to process the captured image (fig. 4, computer 340, image processor 320, memory 345), the processing comprising: i. identifying the patient's skin region within the captured image (para. [0084], Considering Table 2, skin color changes and localized or mottled skin color changes can be detected if camera 120 has color specific detection devices. For example, cameras 120 can have an image sensor array 124 (commonly a CCD or CMOS) including sensing pixels overlaid with a patterned color filter array (often RGB). To some extent, the native resolution of the camera 120 will impact the ability to image some of the conditions on Table 2; Table 1. Skin color (by location, averaged)), ii. analyzing the dominant colors present in the patient's skin region (para. [0084], Considering Table 2, skin color changes and localized or mottled skin color changes can be detected if camera 120 has color specific detection devices. For example, cameras 120 can have an image sensor array 124 (commonly a CCD or CMOS) including sensing pixels overlaid with a patterned color filter array (often RGB). To some extent, the native resolution of the camera 120 will impact the ability to image some of the conditions on Table 2; Table 1. Skin color (by location, averaged)), iii. determining the presence of yellow pigmentation based on the dominant colors (Table 2, Skin color, Yellow: jaundice), and iv. generating and transmitting a notification upon detection of yellow pigmentation (fig. 2A, network 360, para. [0037], [0079], when the physiological monitoring system 300 detects a potential issue, which may reflect a gradual or abrupt physiological change, it is supposed to provide one or more alerts, which can be communicated differently depending on the circumstances. For example, an electronic imaging device 100 can provide an alert locally, via a display 110 (with an icon, for example) or a flashing light, an audio tone, but the detailed data may only be accessible at another location (to a lead user) on the network 360.); and d. a local communication network facilitating connectivity between the camera, the computing device (fig. 2A, network 360; para. [0022], Electronic imaging device 100 is interconnected to image processing electronics 320, a system controller 330, a computer 340, memory or data storage 345, a communications controller 355, and a network 360.). Gobeyn is silent regarding a light panel integrated with the camera for administering phototherapy to the patient; and a local communication network facilitating connectivity between the camera, the computing device, and the light panel. However, Trau discloses sensor and system for neonatal jaundice monitoring and management (abstract) and teaches a light panel for administering phototherapy to the patient and a local communication network facilitating connectivity between the camera, the computing device, and the light panel (para. [0054], On the phototherapy box 13, there are power 14 and switch 15 that could initiate the sensing module 9 and phototherapy box 13. LEDs 16 are used for the treatment purpose. The intensity of the illumination module or LEDs 16 is controlled by the microprocessor 19, based on the signals sent through a wired/wireless communication 12 from sensing module 9; para. [0021], FIG. 3 schematic illustrating a system to manage jaundice composed of the sensor, a control box and a light module.). Therefore, it would have been obvious to one of ordinary skill in the art, at the time of filing, to modify Gobeyn, by adding a light panel for administering phototherapy to the patient and a local communication network facilitating connectivity between the camera, the computing device, and the light panel, as taught by Trau, for the purpose of treating jaundice (para. [0021]). Trau is silent regarding a light panel integrated with the camera. However, Butler discloses an apparatus for light therapy (abstract) and teaches a light panel integrated with the camera (fig. 3A, para. [0047], the camera 110′ is a charge coupled device (CCD) based digital camera that is located in an interior opening 310 of the LED array 102′). Therefore, it would have been obvious to one of ordinary skill in the art, at the time of filing, to modify Gobeyn as modified by Trau, by configuring a light panel to be integrated with the camera, as taught by Butler, for the purpose of having a compact design of the system. Re Claim 6, Gobeyn discloses a method for monitoring jaundice using a computer-based system, comprising the steps of: a. capturing images of a patient using a camera (para. [0084], fig. 4, cameras 120 can have an image sensor array 124 (commonly a CCD or CMOS) including sensing pixels overlaid with a patterned color filter array (often RGB)); b. processing the captured images by a computing device in communication with the camera (fig. 4, computer 340, image processor 320, memory 345), the processing comprising: i. identifying the patient’s skin region within the captured image (para. [0084], Considering Table 2, skin color changes and localized or mottled skin color changes can be detected if camera 120 has color specific detection devices. For example, cameras 120 can have an image sensor array 124 (commonly a CCD or CMOS) including sensing pixels overlaid with a patterned color filter array (often RGB). To some extent, the native resolution of the camera 120 will impact the ability to image some of the conditions on Table 2; Table 1. Skin color (by location, averaged)), ii. analyzing the dominant colors within the patient’s skin region (para. [0084], Considering Table 2, skin color changes and localized or mottled skin color changes can be detected if camera 120 has color specific detection devices. For example, cameras 120 can have an image sensor array 124 (commonly a CCD or CMOS) including sensing pixels overlaid with a patterned color filter array (often RGB). To some extent, the native resolution of the camera 120 will impact the ability to image some of the conditions on Table 2; Table 1. Skin color (by location, averaged)), iii. determining whether the dominant colors exhibit yellow pigmentation indicative of jaundice (Table 2, Skin color, Yellow: jaundice), and iv. generating a notification upon detection of yellow pigmentation (fig. 2A, network 360, para. [0037], [0079], when the physiological monitoring system 300 detects a potential issue, which may reflect a gradual or abrupt physiological change, it is supposed to provide one or more alerts, which can be communicated differently depending on the circumstances. For example, an electronic imaging device 100 can provide an alert locally, via a display 110 (with an icon, for example) or a flashing light, an audio tone, but the detailed data may only be accessible at another location (to a lead user) on the network 360.). Gobeyn is silent regarding administering phototherapy to the patient using a light panel integrated with the camera. However, Trau discloses sensor and system for neonatal jaundice monitoring and management (abstract) and teaches administering phototherapy to the patient using a light panel (para. [0054], On the phototherapy box 13, there are power 14 and switch 15 that could initiate the sensing module 9 and phototherapy box 13. LEDs 16 are used for the treatment purpose. The intensity of the illumination module or LEDs 16 is controlled by the microprocessor 19, based on the signals sent through a wired/wireless communication 12 from sensing module 9; para. [0021], FIG. 3 schematic illustrating a system to manage jaundice composed of the sensor, a control box and a light module.). Therefore, it would have been obvious to one of ordinary skill in the art, at the time of filing, to modify Gobeyn, by adding a step of administering phototherapy to the patient using a light panel, as taught by Trau, for the purpose of treating jaundice (para. [0021]). Trau is silent regarding a light panel integrated with the camera. However, Butler discloses an apparatus for light therapy (abstract) and teaches a light panel integrated with the camera (fig. 3A, para. [0047], the camera 110′ is a charge coupled device (CCD) based digital camera that is located in an interior opening 310 of the LED array 102′). Therefore, it would have been obvious to one of ordinary skill in the art, at the time of filing, to modify Gobeyn as modified by Trau, by configuring a light panel to be integrated with the camera, as taught by Butler, for the purpose of having a compact design of the system. Re Claim 2, Gobeyn discloses a monitoring device, connected the local communication network, for receiving the notification and patient data (fig. 2A, network 360, para. [0037], [0079], when the physiological monitoring system 300 detects a potential issue, which may reflect a gradual or abrupt physiological change, it is supposed to provide one or more alerts, which can be communicated differently depending on the circumstances. For example, an electronic imaging device 100 can provide an alert locally, via a display 110 (with an icon, for example) or a flashing light, an audio tone, but the detailed data may only be accessible at another location (to a lead user) on the network 360.). Re Claim 3, Gobeyn discloses that the computing device utilizes machine learning algorithms for improved accuracy in determining yellow pigmentation (para. [0037], The wellness parameters 410 are principally physiological metrics, which can be input by users 10, or derived from the image data captured by cameras 120, or calculated during subsequent analyses. Generally the wellness parameters 410 quantify various wellness, health, and medical conditions or attributes. Once these wellness parameters 410 are calculated and stored to a memory 345, an inference engine 400 (which is functionally supported by a computer 340) is utilized in the subsequent step to assess the status of physiological conditions. The inference engine 400, which can be algorithm based, or utilize artificial intelligence (AI) or learning methods, is tasked to follow and assess previously identified physiological trends for its subjects (users 10). It is also intended to look for changes, in the physiological data (wellness parameters 410), subtle or otherwise, that might be indicative of previously unidentified physiological changes; para. [0084], As shown in Table 2, there is a wide range of wellness, health, and medical conditions that can potentially be monitored using this system, using one or more wellness parameters 410 (see Table 1). Table 2, Skin color, Yellow: jaundice.). Re Claim 4, Gobeyn as modified by Trau and Butler discloses the claimed invention substantially as set forth in claim 1. Gobeyn discloses that the local communication network is a wireless network (fig. 2A, network 360; para. [0022], Communication controller 355 acts as interface to a communication channel, such as a wireless or wired network 360, for transferring image and other data from one site to the other.). Gobeyn is silent regarding Wi-Fi or Bluetooth technology. However, Trau discloses that the local communication network is a wireless network utilizing Wi-Fi (para. [0054], The data mentioned above from sensing module 9 and phototherapy box 13 may permit sharing between doctor's offices and wards, through USB 23 or WIFI/BLE 21.). Therefore, it would have been obvious to one of ordinary skill in the art, at the time of filing, to modify Gobeyn as modified by Trau and Butler, by configuring the local communication network to be a wireless network utilizing Wi-Fi, as taught by Trau, for the purpose of transmitting data between devices for treatment and because such a modification would have been obvious to try. Re Claim 5, Gobeyn as modified by Trau and Butler discloses the claimed invention substantially as set forth in claim 1. Gobeyn is silent regarding wherein the light panel is adjustable in intensity to provide controlled phototherapy to the patient. However, Trau discloses sensor and system for neonatal jaundice monitoring and management (abstract) and teaches that the light panel is adjustable in intensity to provide controlled phototherapy to the patient (para. [0054], On the phototherapy box 13, there are power 14 and switch 15 that could initiate the sensing module 9 and phototherapy box 13. LEDs 16 are used for the treatment purpose. The intensity of the illumination module or LEDs 16 is controlled by the microprocessor 19, based on the signals sent through a wired/wireless communication 12 from sensing module 9. Para. [0056], The sensing module will provide the bilirubin concentration or the change of the bilirubin in the body, thus, provide guidance or instructions to the phototherapy device which could regulate the intensity of the light treatment to a subject, the and inform caregivers by a buzzer when there is any change of the intensity.). Therefore, it would have been obvious to one of ordinary skill in the art, at the time of filing, to modify Gobeyn as modified by Trau and Butler, by configuring the light panel to be adjustable in intensity to provide controlled phototherapy to the patient, as taught by Trau, for the purpose of providing proper dose to the patient (para. [0054], [0056]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to VYNN V HUH whose telephone number is (571)272-4684. The examiner can normally be reached Monday to Friday from 9 am to 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Benjamin Klein can be reached at (571) 270-5213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Benjamin J Klein/Supervisory Patent Examiner, Art Unit 3792 /V.V.H./ Vynn Huh, September 16, 2026Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Sep 27, 2024
Application Filed
Sep 29, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778435
AN APPARATUS AND A METHOD FOR MEASURING JUGULAR VEIN PRESSURE WAVEFORM
3y 5m to grant Granted Nov 03, 2026
Patent 12779219
METHODS FOR APPLYING AN ELECTRICAL SIGNAL TO A SUBJECT
1y 9m to grant Granted Nov 03, 2026
Patent 12728263
Delivering Tumor Treating Fields (TTFields) to the Neck, Thoracic Spine, and Optic Tract
1y 10m to grant Granted Sep 08, 2026
Patent 12727775
PORTABLE DEVICE FOR QUANTITATIVE MEASUREMENT OF TISSUE AUTOREGULATION AND NEUROVASCULAR COUPLING USING EEG, METABOLISM, AND BLOOD FLOW DIAGNOSTICS
1y 8m to grant Granted Sep 08, 2026
Patent 12714846
BLOOD PUMP SYSTEM
2y 1m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
99%
With Interview (+44.4%)
3y 5m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 294 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month